![James Geraghty](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 1 M $ al 31/05/2026
James Arthur Geraghty was the founder of rEVO Biologics, Inc., founded in 1993, where the title held was Chairman, President & Chief Executive Officer.
Current jobs include Chairman at Catalent JNP, Inc.; Chairman at Orchard Therapeutics (Europe) Ltd. since 2018; Director at Bio Ventures for Global Health since 2010; Director at Therapeutic Human Polyclonals, Inc.; Independent Director at Voyager Therapeutics, Inc. since 2014; Independent Non-Executive Director at CANbridge Life Sciences Ltd. since 2017; Independent Director at Fulcrum Therapeutics, Inc. since 2016; and Independent Non-Executive Director at CANbridge Pharmaceuticals Inc. since 2018.
Former jobs include Chairman at Catalent JNP, Inc. from 2015 to 2018; Chairman at Idera Pharmaceuticals, Inc. from 2013 to 2024; Chairman at OMass Therapeutics Ltd. from 2023 to 2026; Chairman at Orchard Therapeutics Plc from 2018 to 2024; Chairman at Pieris Pharmaceuticals, Inc. from 2017 to 2024; Director at ImmuneXcite, Inc.; Director at Genetix Biotherapeutics, Inc.; Director at Aceragen, Inc. from 2021 to 2023; Vice President-Marketing & Strategic Planning at Caremark International, Inc.; Senior Vice President-International Development at Genzyme Corp.
from 2007 to 2011; Trustee at Joslin Diabetes Center, Inc.; Senior Vice President at Third Rock Ventures LLC from 2013 to 2016; President at Sanofi BV from 1998 to 2000; Senior VP-Strategy & Business Development at Sanofi from 2012 to 2013.
Education includes graduate degrees from the University of Pennsylvania and Yale Law School, and an undergraduate degree from Georgetown University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 31/03/2026 | 90.714 ( 0,14 % ) | 627 741 $ | 31/05/2026 | |
| 09/06/2026 | 70.588 ( 0,12 % ) | 273 176 $ | 31/05/2026 | |
| 12/01/2026 | 700.000 ( 0,12 % ) | 181 307 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| VOYAGER THERAPEUTICS, INC. | Director/Miembro de la Junta | 01/01/2014 |
| FULCRUM THERAPEUTICS, INC. | Director/Miembro de la Junta | 19/07/2016 |
| JUNIPER PHARMACEUTICALS INC | Presidente | - |
| CANBRIDGE PHARMACEUTICALS INC. | Director/Miembro de la Junta | 18/07/2018 |
CANbridge Life Sciences Ltd.
 CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Produces biopharmaceutical products | Director/Miembro de la Junta | 01/05/2017 |
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Researches on transformative gene therapies | Presidente | 29/06/2018 |
Bio Ventures for Global Health
 Bio Ventures for Global Health Bio Ventures for Global Health is an organization focused on leveraging biotechnology to address global health challenges. The non-profit company is based in Washington, DC. It collaborates with various stakeholders to develop innovative solutions for diseases that disproportionately affect low-resource settings. Through strategic partnerships and initiatives, the company aims to improve health outcomes and access to healthcare in underserved communities worldwide. The CEO of the company is James C. Greenwood. | Director/Miembro de la Junta | 12/10/2010 |
Therapeutic Human Polyclonals, Inc.
 Therapeutic Human Polyclonals, Inc. Pharmaceuticals: MajorHealth Technology Develops human antibody therapeutics | Director/Miembro de la Junta | - |
| Empresas | Cargo | Fin |
|---|---|---|
OMass Therapeutics Ltd.
 OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Develops native mass spectrometry platform | Presidente | 28/01/2026 |
| ░░░░░░ ░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 25 |
|---|---|
Catalent JNP, Inc.
 Catalent JNP, Inc. Miscellaneous Commercial ServicesCommercial Services Specializes in research and development of drugs & therapeutics | Commercial Services |
Caremark International, Inc.
 Caremark International, Inc. Medical/Nursing ServicesHealth Services Provides home healthcare services | Health Services |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
ImmuneXcite, Inc.
 ImmuneXcite, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which develops monoclonal antibodies for cancer | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
bluebird bio, Inc.
 bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
Georgetown University
 Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bio Ventures for Global Health
Bio Ventures for Global Health Bio Ventures for Global Health is an organization focused on leveraging biotechnology to address global health challenges. The non-profit company is based in Washington, DC. It collaborates with various stakeholders to develop innovative solutions for diseases that disproportionately affect low-resource settings. Through strategic partnerships and initiatives, the company aims to improve health outcomes and access to healthcare in underserved communities worldwide. The CEO of the company is James C. Greenwood. | |
Therapeutic Human Polyclonals, Inc.
Therapeutic Human Polyclonals, Inc. Pharmaceuticals: MajorHealth Technology Develops human antibody therapeutics | Health Technology |
Joslin Diabetes Center, Inc.
 Joslin Diabetes Center, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for diabetes | Health Technology |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm targets companies operating in the fields of the healthcare sector. It provides financing for early stage capital requirements. It acts as a lead investor. | Finance |
Genzyme Europe BV
 Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical & biotherapeutic products | Health Technology |
rEVO Biologics, Inc.
 rEVO Biologics, Inc. BiotechnologyHealth Technology Develops and commercializes specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions | Health Technology |
Yale Law School
 Yale Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Voyager Therapeutics, Inc.
 Voyager Therapeutics, Inc. BiotechnologyHealth Technology Develops gene therapies for fatal and debilitating diseases of the central nervous system | Health Technology |
CANbridge Life Sciences Ltd.
CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Produces biopharmaceutical products | Health Technology |
Pieris Pharmaceuticals, Inc.
 Pieris Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and markets an anticalin-brand protein technology | Health Technology |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Researches on transformative gene therapies | Health Technology |
Fulcrum Therapeutics, Inc.
 Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
OMass Therapeutics Ltd.
OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Develops native mass spectrometry platform | Commercial Services |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc BiotechnologyHealth Technology Engages in research and advancements of gene therapy to develop potential cures for genetic & other severe diseases | Health Technology |
CANbridge Pharmaceuticals Inc.
 CANbridge Pharmaceuticals Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Aceragen, Inc.
 Aceragen, Inc. BiotechnologyHealth Technology Discovers, develops, and commercializes therapeutics for oncology and rare diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
